Immune response to a new hepatitis B vaccine in healthcare workers who had not responded to standard vaccine: Randomised double blind dose-response study

British Medical Journal

Volumn 314, Issue 7077, 1997, Pages 329-333

  Zuckerman, Jane N ^a   Sabin, Caroline ^a   Craig, Fiona M ^b   Williams, A ^b   Zuckerman, Arie J ^a,c  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b Evans House   (United Kingdom)

^c Department of Medical Microbiology ^*

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B ANTIBODY; RECOMBINANT HEPATITIS B VACCINE;

ADULT; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; HEALTH CARE PERSONNEL; HEPATITIS B; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; VACCINATION; VIRUS IMMUNITY;

EID: 0031034072     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.314.7077.329     Document Type: Article

References (32)

1. Szmuness W, Stevens CE, Zang EA, Harley EJ, Kellner A. A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B). A Final Report. Hepatology 1981;1:377-85.
2. Hadler SC, Frances DP, Maynard JE, Judson FN, Thompson SE, Echenberg DF. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med 1986;315:209-14.
3. Jilg W, Schmidt M, Deinhardt F. Immnune response to hepatitis B revaccination. J Med Virol 1988;24:377-84.
4. Jilg W, Schmidt M, Zoulek G, Lorbeer B, Wilkse B, Deinhardt F. Clinical evaluation of a recombinant hepatitis vaccine. Lancet 1984;11:1174-5.
5. Westmoreland D, Player V, Heap DC, Hammond A. Immunization against hepatitis B-what can we expect? Epidemiol Infect 1990;104:499-509.
6. Dienstag JL, Werner BG, Polk BF, Snydman DR, Craven DE, Platt R, Hepatitis B Vaccine in health care personnel: safety, immunogenicity, and indicators of efficacy. Ann Intern Med 1984;101:34-40.
7. Craven DE, Awdeh ZL, Kunches LM, Yunis EJ, Dienstag JL, Werner BG. Non-responsiveness to hepatitis B vaccine in health care workers. Ann Intern Med 1986;105:356-60
8. Wood RC, MacDonald KL, White KE, Hedberg CW, Hanson M, Osterholm MT. Risk factors for lack of detectable antibody response following hepatitis B vaccination of Minnesota health care workers. JAMA 1993;270:2935-9.
9. Boag F. Hepatitis B: heterosexual transmission and vaccination strategies. Int J STD and AIDS 1991;2:318-24.
10. Milich DR. Immune response to hepatitis B virus protein relevance of the murine model. Seminars in Liver Disease 1991;11:93-112.
11. Alper CA, Kruskall MS, Marcus-Bagley D, Craven DE, Katz AJ, Brink SJ. Genetic prediction of nonresponse to hepatitis B vaccine. N Engl J Med 1989;321:708-12.
12. Kruskall MS, Alper CA, Awdeh Z, Yunis EJ, Marcus-Bagley D. The immune response to hepatitis B vaccine in humans: inheritance patterns in families. J Exp Med 1992;175:495-502.
13. Milich DR, McNamara NK, McLachlan A, Thornton GB, Chisari FV. Distinct H-2 linked regulation of T-tell responses to the pre-S and S regions of the same hepatitis B surface polypeptide allows circumvention of nonresponsiveness to the S region. Proc Natl Acad Sci USA, 1985;82:8168-72.
14. Milich DR, McLachlan A, Chisari FV, Kent SB, Thornton GB. Immune response to the pre-S(1) region of hepatitis B surface antigen (HBsAg): a pre-S(I)-specific T cell response can bypass nonresponsiveness to the pre-S(2) and S regions of the HBsAg. J Immunol 1986;137:315-22.
15. Arif M, Mitchison NA, Zuckerman AJ. Genetics of nonresponders to hepatitis B surface antigen and possible ways of circumventing "nonresponse". In: Zuckerman AJ, ed. Viral hepatitis and liver disease. New York: Liss, 1988:714-6.
16. Gerlich W, Deepen R, Heerman KH, Krone B, Lu XY, Seifer M. Protective potential of hepatitis B virus antigens other then the S gene protein. Vaccine 1990;8:563-8.
17. Klinkert M, Theilmann L, Pfaff E, Schaller H. Pre-S antigens and antibodies early in the course of acute hepatitis B virus infection. J Virol 1986;58:522-5.
18. Alberti A, Pontisso P, Tagariello GF, Belussi F. Antibody response to pre-S2 and hepatitis B virus induced liver damage. Lancet 1988;i:1421-4.
19. Milich DR, Thornton GB, Neurath AR, Kent SB, Michel M-L, Tiollais P. Enhanced antigen. Science 1985;228:1195-9.
20. Ferrari C, Penna A, Bertoletti A, Cavalli A, Valli A, Schianchi C, et al. The pre-S1 antigen of hepatitis B virus is highly immunogenic at the T cell level in man. J Clin Invest 1989;84:1314-9.
21. Yap I, Guan R, Chan SH. Recombinant DNA hepatitis B vaccine containing pre-S components of the HBV coat protein - a preliminary study on immunogenicity. Vaccine 1992;10:439-42.
22. Shouval D, Ilan Y, Adler R, Deepan R, Panel A, Even-Chen Z. Improved immunogenicity in mice of a mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens as compared with conventional yeast-derived vaccines. Vaccine 1994;12:1453-9.
23. Yap I, Guan R, Chan SH. Study on the comparative immunogenicity of a recombinant DNA hepatitis B vaccine containing pre-S components of the HBV coat protein with non pre-S containing vaccines. J Gastroenterol Hepatol 1995;10:51-5.
24. Yoneyama T, Akatsuka T, Miyamura T. Stable expression of the hepatitis B virus surface antigen containing pre-S2 protein in mouse cells using a bovine papillomavirus vector. J Gen Virol 1988;69:1931-9.
25. Samanta H, Youn BW. Expression of hepatitis B virus surface antigen containing the pre-S region in mammalian cell culture system. Vaccine 1989;7:69-76.
26. Eddleston A. Modem vaccines: hepatitis. Lancet 1990;335:1142-4.
27. Zuckerman JN, Cockcroft A, Zuckerman AJ. Site of injection for vaccination. BMJ 1992;305:1158.
28. Neurath AR, Kent SBH, Strick N. Location and chemical synthesis of a pre-S gene coded immunodominant epitope of hepatitis B virus. Science 1984;224:392-5.
29. BMA. A code of practice for implementation of the UK hepatitis B immunisation guidelines for the protection of patient and staff. London: BMA, 1995.
30. Legler K, Strohmeyer H, Ritter S, Gerlich WH, Thomssen R, Kinetics, subtype specificity and immunoglobulin class of anti-HBs induced by hepatitis B vaccine. Develop Biol Standard 1983;54:179-89.
31. Prince AM, Brotman B, Purcell RF, Gerin JL. A final report on safety and immunisation of a bivalent aqueous subunit HBV vaccine. J Med Virol 1984;15:399-419.
32. Prince AM. Revaccination against hepatitis B. Lancet 1991;ii:61.